1. Introduction {#s0005}
===============

Cannabis remains the most used illegal drug across the world, and while rates of use are generally falling, the incidence of related harm is rising internationally ([@bb0205]). Australia has particularly high rates of use, with 35% of adults reporting lifetime consumption, and 10% using it in the previous 12 months ([@bb0010]).

However, 70--80% of cannabis users stop using it by their mid-thirties ([@bb0035]), and even over 5--6 years, substantial rates of cessation or reduced consumption in adolescents or young adults are seen ([@bb0100], [@bb0145], [@bb0190]). In common with other substances, most successful cessation occurs without treatment ([@bb0045], [@bb0150]). While these changes are typically greatest among infrequent or non-problematic users ([@bb0035]), people with cannabis abuse or dependence also have substantial rates of recovery. For example, an analysis of data from Wave 1 of the National Epidemiologic Survey on Alcohol and Related Conditions ([@bb0005]) found that 81% of people with lifetime cannabis dependence did not meet criteria over the previous year.

While community samples can provide good estimates of the degree and timing of recovery from cannabis use disorder, sample sizes need to be large to provide accurate estimates of these rates. So, a study of 1228 adolescents ([@bb0135]) found only 12 with lifetime cannabis dependence, and the resultant estimate of full remission (32%) therefore had a substantial standard error (26%). Furthermore, treatment trial researchers and services need estimates of remission in treatment seekers.

A study of control groups in treatment studies provides fertile ground for the estimation of changes in treatment seekers who do not receive substantial assistance. These studies have several advantages: high-quality trials typically have diagnostic interviews and other assessments that are able to characterise the samples well, the nature of treatments is standardised or tracked carefully, and substantial effort is put into ensuring that follow-up assessments maximise retention rates. While individual studies often have relatively small sample sizes in their control group, meta-analytic methods provide an opportunity to obtain estimations of effect sizes over multiple studies and substantial samples.

Accordingly, the aim of the current paper was to determine the degree of 'natural recovery' in the control groups from randomised controlled trials on substance use disorders, which reported changes in the frequency of cannabis use. 'Natural recovery' in this article refers to processes where consumption of cannabis is reduced or ceased without professional intervention. It was operationalised as the degree of change in cannabis use within groups receiving inactive or minimal interventions.

2. Methods {#s0010}
==========

Electronic searches were performed in January 2015, to find studies that included a control group that had explored the topic of cannabis use treatment. The search used title, abstract and keywords of Medline, PsycINFO, Psychology Journals, and Psychology Subject Corner. The search terms were: (cannabis OR marijuana OR marihuana OR addiction OR abuse OR substance) AND (treatment OR randomi\* control).

Potential studies were evaluated for inclusion in this study by the first author, based on whether they: (a) provided data on cannabis use, which allowed the calculation of pre--post effect sizes in a group of participants randomised to receive inactive (e.g. waitlist) or minimal interventions (e.g. drug-related information only); (b) were in English; (c) did not comprise case studies or personal accounts; (d) did not include participants with severe mental disorders (i.e., schizophrenia, bipolar disorder, posttraumatic stress disorder, major depressive disorder). In order to report results on a single measure, we restricted the studies to those allowing a calculation of cannabis use in the previous 30 days.

The formal examination of effect sizes used Comprehensive Meta-Analysis ([@bb0015]), and the primary analysis applied a random effects model. This is the appropriate approach to use when samples or treatments are potentially different, regardless of whether significant heterogeneity is evidenced ([@bb0020]). We report effects as standardised mean differences (Cohen\'s d). Analyses of degree of change require estimates of test--retest correlations of the measures, or reported analyses of changes within groups. While Timeline Followback assessments of cannabis use can have a 7--14 day test--retest reliability of 0.92 ([@bb0155]), we do not know the reliability of the 3--12 month assessments of cannabis use in the current trials. We use an estimate of 0.70 for the primary analyses below, but also undertake sensitivity analyses with test--retest correlations of .60 and .80. Where means and standard deviations were reported on different sample sizes at baseline and follow-up, we used the follow-up sample size for the analysis, estimating baseline scores for retained participants from reported data using the full sample. We also present sample-weighted mean days of use at baseline, post and follow-up assessments.

3. Results {#s0015}
==========

The search of cannabis treatment in general population samples elicited 2554 articles. Reviewing article titles to confirm that they met the search criteria left 374, and this number was reduced to 55 after reading abstracts. Further searching using reference lists and cited reference search yielded 12 potential articles, and 3 others were suggested by reviewers. Review papers were examined ([@bb0030], [@bb0060], [@bb0165], [@bb0195]) to identify any additional papers, but none were added from that procedure. A final decision on inclusion was determined after reading the full paper, and any that raised potential questions on inclusion were reviewed by all authors, until consensus was reached. Studies by [@bb0040], [@bb0120], [@bb0095], [@bb0105], [@bb0065], [@bb0140], [@bb0170], [@bb0215], [@bb0115] and [@bb0090] were excluded due to an inability to calculate a within-group effect size on cannabis use per month from the data provided. The control groups of [@bb0175], [@bb0085] and [@bb0025] provided too much support for them to meet inclusion criteria as a control treatment condition.

Details of the eight included studies are displayed in [Table 1](#t0005){ref-type="table"}, their results are provided in [Table 2](#t0010){ref-type="table"} and their methodological quality is summarized in [Table 3](#t0015){ref-type="table"}. The studies had a total of 600 control participants. Average weighted mean days of use in the previous 30 days fell from 24.5 to 19.9 at 2--4 months across the eight studies. Only one of the included studies ([@bb0070]) provided data over a longer follow-up, preventing an assessment of the degree of sustained change across the studies. That study saw little change in use at 12 months (M = 22.1, SD = 9.2).Table 1Studies on treatment of cannabis use in the past 30 days within control groups of general populations: Studies reporting mean values.Author (date)Sample typeBasis of participationDisorderCountryControl groupMeasure[@bb0180]COMWanting help quitting98% current CUDUSDelayed treatment\# days used cannabis per month[@bb0110]COMTreatment100% current CUDUSDelayed treatment% days used cannabis in the past 90[@bb0210]SCHInformation re their CU68% current CUD\
(86% lifetime CUD)USDelayed treatment\# days used cannabis in the past 60[@bb0185]COMFeedback on CU (not treatment)93% current CUDUSDelayed feedback\# days used cannabis per week[@bb0125]COM + OPInformation, discussion85% CUDAUDelayed treatment\# days used cannabis in the past 90[@bb0070]UNI...[1](#tf0005){ref-type="table-fn"}CUCANGeneral health information\# days used cannabis in the past 30[@bb0075]COMInformation or counselling on CU concerns98% probable CUD on SDSAUDelayed treatment\# days used cannabis in the past 28[@bb0160]COMWanting to reduce or cease CUCUAUCannabis information\# days used cannabis in past month[^1][^2][^3][^4][^5]Table 2Mean days of cannabis use in the past 30 days, in control groups of treatment trials on people with cannabis use disorders.StudyBaseline2--4 monthsNMSDNMSD[@bb0180]8624.96.17917.110.7Litt et al. (2005)[1](#tf0010){ref-type="table-fn"}14830.04.714825.210.2Walker et al. (2006)[2](#tf0015){ref-type="table-fn"}5018.48.55016.410.3Stephens et al. (2007)[3](#tf0020){ref-type="table-fn"}6426.08.26424.68.2Martin and Copeland (2008)[4](#tf0025){ref-type="table-fn"}2018.510.52018.210.5[@bb0070]3223.96.13223.16.9Gates et al. (2012)[5](#tf0030){ref-type="table-fn"}8123.96.36113.412.2[@bb0160]11920.88.75814.18.8Total N, weighted mean60024.551219.9[^6][^7][^8][^9][^10][^11]Table 3Methodological review of control treatments from the included randomised controlled trials.StudySymptom/diagnostic measureTreatment received by controlsFollow-up retentionIntention to treat (and management of missing data)Single-blind follow-up[@bb0180]CUD: Self-report\
CU: Self & collateral reportBL: No current formal treatment\
4 mths: 6% had treatment\
18% in self-help groups92% to 4 mthsNoNo---Self-report (phone interview if no response)[@bb0110]CUD: SCID\
CU: TLFB, Self & collateral report, urinalysis.BL: No current Mj therapy, self-help group\
4 mths: NR93% to 4 mthsNo (Secondary analyses: BL substitution)No[@bb0210]CUD: GAIN\
CU: Self-reportNR98% to 3 mthsNoNR---Self-report; different staff at follow-up[@bb0185]CUD: SCID\
CU: TLFB, self-report, urinalysis.BL: No current Mj therapy, self-help group\
At 7-wks, 6 & 12 mths:\
1--4% of whole sample in treatment\
2--7% in self-help groups97% at 7 wksYes\
(BL substitution. Checked with imputation, omission)No[@bb0125]CUD: Structured interview (GAIN) & self-report (SDS)\
CU: TLFB, self-report, urinalysis.BL: No treatment in previous 90 days\
3 mths: NR80% at 3 mthsYes\
(BL substitution)NR (Independent researcher)[@bb0070]CU: Interviewer-administered questionnaireNR52% at 12 mthsNo\
Analysed completers of all assessmentsNR[@bb0075]Probable CUD: SDS\
CU: TLFB, self-report.BL: No current Mj therapy\
3 mths: 46% sought treatment, 39% used medication75% at 3 mthsYes\
(Multiple imputation)No[@bb0160]CUD: GAIN\
CU: TLFB, Self-reportBL: No formal Mj treatment in last 3 mths\
3 mths: Excluded 4% who had treatment66% at 6 wks\
52% at 3 mthsNo (Complier average causal effect analyses. Checked with LOCF, omission)Automated self-report[^12][^13][^14][^15]

Results of the meta-analysis using a test--retest correlation of .70 are displayed in [Fig. 1](#f0005){ref-type="fig"}. The figure displays the average effect using a fixed-effects model. With a random effects model, there was an average change in cannabis use of −.442 SD (CI: −.657 to −.228), which was highly significant (*p* \< .001). A test of heterogeneity gave Q (7) = 57.71, *p* \< .001, providing support for the selection of the random effects model. Examination of the classic fail-safe N found that 293 missing studies would be required to give *p* \> .05. Sensitivity analyses using random-effects models and test--retest correlations of .60 (−.460, CI: −.685 to −.235) and .80 (−.415, CI: −.613 to −.217) made little difference to the result.Fig. 1Control group changes over 2--4 months in non-psychotic groups.

Four studies specifically targeted people who wanted to quit or reduce cannabis use, or recruited them for an intervention trial ([Table 1](#t0005){ref-type="table"}). The remainder recruited people for information or discussion about their cannabis use. Inspection of [Fig. 1](#f0005){ref-type="fig"} shows that the latter group included three of the four studies with weaker effects ([@bb0125], [@bb0185], [@bb0210]), but it also included the trial with the strongest effects ([@bb0075]).

An evaluation of the methodological quality of the control group data is in [Table 2](#t0010){ref-type="table"}. A strength of the studies was their follow-up rates over the control period, with six having rates of 75% or above and four having rates above 90%. None clearly had single-blind follow-up, but two studies had an independent assessor conducting the follow-up, and three used only self-report. Four studies checked participant reports of cannabis use during follow-up against collateral data or urinalysis. All but two studies verified that most participants had a cannabis use disorder, although only two used a gold-standard structured clinical interview. A significant potential threat to the interpretation of results as being reflective of unassisted recovery was the lack of reports on other concurrent treatment in four trials, and a high level of reported treatment in one ([@bb0075]). Every study had at least one significant issue that should induce caution in the interpretation of its results.

4. Discussion {#s0020}
=============

Control groups from the eight randomised controlled trials showed a significant mean reduction in days of cannabis use. At 2--4 months\' follow up, participants used cannabis on 4.6 fewer days a month than at baseline, reflecting over one additional day of abstinence each week, and giving a total of more than a week of total abstinence each month. The average effect size of −.415 to −.442 SD offers a challenging base from which treatment effects are to be obtained. Our results will assist in minimum sample size calculations for randomised controlled trials, and provide a yardstick for the evaluation of changes from services for cannabis misuse.

While we regard these self-initiated changes as substantial, they fall short of major changes in sustained cessation, which supports the contention that self-initiated cannabis cessation is difficult. This observation is consistent with a comparison of reviews on placebo interventions for different substances by [@bb0130], which found that nicotine provided the lowest abstinence rate (8%), followed by cannabis (15%) and alcohol (18%), with opioids (44%) and cocaine (47%) providing the strongest responses. While the meta-review potentially resulted in multiple counting of trials and there were few cannabis trials in a single included review, the study highlighted the limited nature of cannabis cessation rates, even in placebo conditions.

Interpretation of our results must be moderated by the issues raised in our methodological review of the studies, which identified at least one significant limitation in every study. Perhaps most important was the potential for other treatment to have been responsible for at least some of the observed reductions in cannabis use. The results highlight areas for future improvement of randomised controlled trials on cannabis use disorder that will not only provide increased confidence in the estimates of change in control groups, but also in the reported outcomes of the whole trial.

While there has been research into unassisted cessation of substance misuse for more than 40 years ([@bb0030], [@bb0165]), it is only in the last 15 that this work has focused specifically on cannabis. To our knowledge, the current review is the first to examine 'natural recovery' in the control groups of randomised controlled trials. Regression to the mean may account for some of the observed change, but our results are consistent with population studies ([@bb0005], [@bb0135]), which have similarly observed the potential for recovery from both cannabis use and cannabis dependence, suggesting that at least some individuals can reduce their cannabis use without significant help.

A limitation of this review was the fact that the initial literature search relied on one author, although the resolution of any identified issues and final decisions on inclusion were by consensus of all authors, and no additional papers were identified from reviews. Other limitations included the small number of identified trials with control groups that had no or minimal treatment, and the fact that minimal treatment controls can typically be conducted for periods of only 2--4 months at most. We excluded eight studies because of an absence of data on cannabis consumption over a specific period, in order to preserve comparability of the results across studies: if those studies had provided consumption data, we could potentially have doubled the number of studies in our review. We recommend that future studies routinely include both abstinence rates and average consumption data as part of their results ([@bb0140]). However, despite the restricted number of studies, the total sample size of 600 provided a substantial group for estimation of consumption changes.

5. Conclusions {#s0025}
==============

This is the first meta-analysis to explore changes in cannabis use in control conditions of treatment studies. Results of the current study demonstrate that modest average reductions in the frequency of average cannabis use can be seen, although there was substantial variability in effect size between studies, and some uncertainty over the potential role of outside treatment in the effects. The study gives weight to further exploration of the concept of natural recovery in people with cannabis use disorders and provides researchers and practitioners a baseline from which to estimate likely changes or needed effects sizes in intervention studies.

[^1]: AU: Australia; CAN: Canada; US: United States of America;

[^2]: OP: Outpatients; COM: Community; HM: Homeless/unstably housed; SCH: School; UNI: University;

[^3]: CU: Cannabis use; CUD: Cannabis use disorder (DSM-IIR or DSM-IV Cannabis Dependence or Abuse);

[^4]: SDS: Severity of Dependence Scale ([@bb0080]).

[^5]: Mass advertising described the intervention study. Specific details on the basis of participation are not provided.

[^6]: Conversion formulae from reported means (M) to give days of use in the past 30 days:.

[^7]: \% days used in past 90: M × 30.

[^8]: Days used in past 60: M/2.

[^9]: Days per week: (M/7) × 30.

[^10]: Days used in past 90: M/3.

[^11]: Days used in past 28: (M/28) × 30.

[^12]: CU: Cannabis use; CUD: Cannabis Use Disorder;

[^13]: SCID: Structured Interview for DSM-IV; GAIN: Global Appraisal of Individual Needs (Initial or final) ([@bb0050], [@bb0055]);

[^14]: TLFB: Timeline Follow-Back; SDS: Severity of Dependence Scale ([@bb0080]);

[^15]: LOCF: Last observation carried forward; BL: Baseline; Mj: Marijuana; NR: Not Reported.
